NCT06641895View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2030

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
GENETIC

BBM-D101

BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.

Trial Locations (1)

200127

RECRUITING

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Shanghai Mianyi Biopharmaceutical Co., Ltd.

UNKNOWN

lead

Shanghai Jiao Tong University School of Medicine

OTHER